Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Malignant pleural mesothelioma (MPM) is an aggressive malignancy tightly associated with asbestos exposure. The increasing incidence of MPM and its resistance to all therapeutic modalities necessitate an urgent development of new treatments for MPM. Proteasome inhibitors (PIs) have emerged as promising agents for treating human cancers that are refractory to current chemotherapies. In this study, we characterized MG132, a commonly used PI, for its proapoptotic and anti-invasion activities in NCI-H2452 and NCI-H2052 human thoracic MPM cell lines to determine the therapeutic effect of PIs on MPM. We found that as low as 0.5 microM MG132 caused a significant apoptosis in both cell lines as evidenced by DNA damage, cleavage of poly ADP-ribose polymerase and caspases 3, 7, and 9, and mitochondrial release of Smac/DIABLO and Cytochrome c. Mitochondrial caspase activation was found to be the underlying mechanism of the MG132-induced apoptosis. Mcl-1, among the Bcl-2 and IAP (inhibitor of apoptosis protein) antiapoptotic family proteins tested, was proved to be a major inhibitor of the MG132-induced apoptosis in MPM cells. Meanwhile, subapoptotic doses of MG132 inhibited the invasion of both MPM cell lines through reducing Rac1 activity. These observations demonstrate that MG132 possesses proapoptotic and anti-invasion activities in human MPM cells, therefore encouraging further investigations on the value of PIs for treating MPM.
Yuan
Bao-Zhu
BZ
Laboratory of Molecular Genetics, Toxicology and Molecular Biology Branch, National Institute for Occupational Safety and Health, CDC, Morgantown, WV 26505, USA.
Chapman
Joshua A
JA
Reynolds
Steven H
SH
IUBMB Life. 2002 Feb;53(2):115-9
12049193
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20
7682708
Apoptosis. 2007 Sep;12(9):1543-68
17573556
Cancer Res. 2006 Jan 1;66(1):352-61
16397249
J Biol Chem. 2006 Mar 3;281(9):5750-9
16380381
EMBO J. 1998 Jul 15;17(14):4066-74
9670021
Semin Oncol. 1981 Sep;8(3):313-20
7280715
Clin Cancer Res. 2002 Apr;8(4):945-54
11948098
Cell Death Differ. 2005 Sep;12(9):1240-54
16094404
Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii
16325127
Annu Rev Biochem. 2004;73:87-106
15189137
Curr Oncol Rep. 2005 Jul;7(4):260-5
15946584
J Biol Chem. 2004 Aug 20;279(34):35849-57
15152002
Clin Cancer Res. 2005 Mar 15;11(6):2300-4
15788680
Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58
17522864
Curr Opin Genet Dev. 2002 Feb;12(1):36-43
11790552
J Biol Chem. 2002 Sep 27;277(39):36611-6
12121969
Oncogene. 2003 Nov 24;22(53):8590-607
14634621
Int J Biochem Cell Biol. 2005 Feb;37(2):267-71
15474972
Eur J Cancer. 2006 Nov;42(16):2706-14
16989994
Cell. 1987 Apr 10;49(1):1-4
3030562
Am J Epidemiol. 1997 Feb 1;145(3):211-8
9012593
J Biol Chem. 2000 Jul 21;275(29):22136-46
10766760
Clin Cancer Res. 2005 Nov 15;11(22):8122-30
16299245
Pathol Oncol Res. 2006;12(3):133-42
16998592
J Clin Oncol. 2003 Jul 15;21(14):2636-44
12860938
Leukemia. 2002 Apr;16(4):444-54
11960321
Mol Cancer Ther. 2007 Jul;6(7):1962-72
17620427
Biochem Biophys Res Commun. 1999 Jun 24;260(1):105-10
10381351
Cancer Cell. 2004 May;5(5):417-21
15144949
Cell. 2005 Jul 1;121(7):1085-95
15989957
Genes Dev. 1998 Jun 1;12(11):1551-70
9620844
Genes Dev. 2003 Jun 15;17(12):1475-86
12783855
Cancer Lett. 2006 Feb 8;232(2):161-9
16458112